Editas Medicine
Data Breaches and Security Report

https://editasmedicine.com  ᛫ 
Last updated August 24, 2019

Company Details

Company Overview

Editas Medicine is a discovery-phase pharmaceutical company based in Cambridge, Massachusetts which aims to develop therapies based on CRISPR–Cas9 gene editing technology. It was founded in 2013 with funding from Third Rock Ventures, Polaris Partners and Flagship Ventures and licensed CRISPR patents from the Broad Institute's Feng Zhang, patents from Harvard's David Liu and George Church and patents from Partners Healthcare-MGH's J. Keith Joung.

Valuation

Employees

CEO

Location

Data Breaches and Security News

Security Rating

Sorry, this security report couldn't be loaded at this time. Please try again later.

UpGuard's Cyber Security Ratings range from 0 to 950. The higher the score, the more effective a company is in implementing good security practices.

Passed Checks

Passed{{ passedCheck.passTitle }}

Failed Checks

Warning{{ failedCheck.failTitle }}

View a free security report for Editas Medicine

Get full security report ›

Related posts

Learn more about the latest issues in cybersecurity

More security reports

Compare Editas Medicine's security performance with other companies